Eli Lilly's Alzheimer's drug falls short for accelerated approval from the FDA
![](/46/pdcnewsitem/11/98/45/784x590%20news%20header%20(68).png)
Eli Lilly's Alzheimer's drug donanemab is rejected for accelerated approval by the US FDA, but the clinical trial data still shows promise for coming up for standard approval later in the year.
The much anticipated ruling from the US FDA on Eli Lilly’s Alzheimer’s drug has been released, with the regulators rejecting the application for accelerated approval of donanemab.
The FDA explained its rejection of the experimental drug from Eli Lilly was due to a lack of trial data from patients who had been treated with the drug for a minimum of one year.
The drug, donanemab, is a humanised monoclonal antibody that actively removes amyloid plaques from the brains of those with early-stage Alzheimer’s disease. There has been some concern over using these antibodies in patients as they can cause microhaemorrhages in the brain, but this hasn’t been shown when donanemab has been tested. However, the FDA have noted that not enough trial data exists for them to fully rule out any concerns.
Eli Lilly received a complete response letter from the FDA regarding donanemab, which is likely to stipulate the standards that need to be met for the drug to be approved.
The FDA had issued the letter "due to the limited number of patients with at least 12 months of drug exposure data provided in the submission," Eli Lilly stated.
Lilly points out that patients in the mid-stage trial who achieved clearance of the amyloid plaques in their brains then stopped the treatment. This typically took around six months in 40% of patients.
"I don't think it says anything negative about the drug. It was just a manifestation of the study design," commented Dr Ronald Petersen, an Alzheimer's expert at the Mayo Clinic in Rochester, MN, USA.
The drug is still undergoing a Phase III trial to further confirm results, with this data hopefully supporting the current information, which altogether will be used in the next application for FDA approval later in the year.
"I don't see this is an impediment to the process or timeline in any way," remarked Dr Eric Reiman, Executive Director of Banner Alzheimer's Institute. "When the Phase III trial reads out, I understand it will have that safety data in at least 100 people."
Chief Operating Officer Russ Paulsen from UsAgainstAlzheimer's stated that the advocacy group was "disappointed this treatment won’t be made available to patients sooner," but was encouraged by the reason. "Donanemab worked too well... The FDA requires a minimum of 100 patients to be on the drug for at least 12 months but, due to donanemab's quick action in some patients, many were able to stop treatment in as little as six months," he put in an email.
The nuance of accelerated approval from the US FDA means that approval can only be granted if the measurement of an indicator correlates directly to an improvement in patient response and outcomes. Therefore longer-term clinical data is necessary to fully evaluate the patient outcomes.
Related News
-
News On Track at Pharmapack 2024 - The Track Sponsor interview: BD Pharmaceuticals
January 2024 brings both a new year and Europe’s leading packaging and drug delivery event. Bringing the world’s experts in pharmaceutical packaging together in Paris, France, Pharmapack 2024 brings exciting opportunities to learn and colla... -
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News Roche breaks into the obesity drug market with the acquisition of Carmot Therapeutics
In a bid to diversify their therapeutic offerings, Roche takes over Carmot Therapeutics in $2.7 billion deal, with one obesity drug spearheading the venture into the field as they prep for a Phase II in-human trial. -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News Women in Pharma: Delivering solutions for gender diversity
In our new monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona Speaker Interview – What the US FDA’s Quality Management Maturity Means for the Pharma Industry
At CPHI Barcelona (24–26 October, 2023), we spoke to Sireesha Yadlapalli, CEO of Pharmatech Associates, who gave a presentation on the implications of the US FDA’s Quality Management Maturity (QMM) Initiative, and spoke on the panel of the ... -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News Wegovy and weight-loss drugs driving demand for manufacturers that can fill syringes
Injectable weight-loss treatments are prompting contract manufacturers to invest and include fill-finish services into their service portfolios, in a bid to attract pharmaceutical giants developing drugs similar to Novo Nordisk's Wegovy.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance